US Patent

US12194022 — Use of amisulpride as an anti-emetic

Method of Use · Assigned to Acacia Pharma Ltd · Expires 2031-03-10 · 5y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of amisulpride as an anti-emetic for treating nausea, vomiting, or retches.

USPTO Abstract

Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.

Drugs covered by this patent

Barhemsys (AMISULPRIDE) · Acacia

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1744`	—	Barhemsys
`U-1744`	—	Barhemsys

Patent Metadata

Patent number: US12194022
Jurisdiction: US
Classification: Method of Use
Expires: 2031-03-10
Drug substance claim: No
Drug product claim: No
Assignee: Acacia Pharma Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.